Ann Lab Med.  2023 Nov;43(6):529-530. 10.3343/alm.2023.43.6.529.

New Issues With Neutrophil Gelatinase-associated Lipocalin in Acute Kidney Injury

• Cho SY
• Hur M

• KMID: 2552021
• DOI: http://doi.org/10.3343/alm.2023.43.6.529

Reference

1. Ronco C, Bellomo R, Kellum JA. 2019; Acute kidney injury. Lancet. 394:1949–64. DOI: 10.1016/S0140-6736(19)32563-2. PMID: 31777389.

2. Marakala V. 2022; Neutrophil gelatinase-associated lipocalin (NGAL) in kidney injury - a systematic review. Clin Chim Acta. 536:135–41. DOI: 10.1016/j.cca.2022.08.029. PMID: 36150522.

3. Albert C, Zapf A, Haase M, Röver C, Pickering JW, Albert A, et al. 2020; Neutrophil gelatinase-associated lipocalin measured on clinical laboratory platforms for the prediction of acute kidney injury and the associated need for dialysis therapy: a systematic review and meta-analysis. Am J Kidney Dis. 76:826–41.e1. DOI: 10.1053/j.ajkd.2020.05.015. PMID: 32679151. PMCID: PMC8283708.

4. Albert C, Haase M, Albert A, Zapf A, Braun-Dullaeus RC, Haase-Fielitz A. 2021; Biomarker-guided risk assessment for acute kidney injury: time for clinical implementation? Ann Lab Med. 41:1–15. DOI: 10.3343/alm.2021.41.1.1. PMID: 32829575. PMCID: PMC7443517.

5. Hoste EA, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, et al. 2015; Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 41:1411–23. DOI: 10.1007/s00134-015-3934-7. PMID: 26162677.

6. Yang HS, Hur M, Lee KR, Kim H, Kim HY, Kim JW, et al. 2022; Biomarker rule-in or rule-out in patients with acute diseases for validation of acute kidney injury in the emergency department (BRAVA): a multicenter study evaluating urinary TIMP-2/IGFBP7. Ann Lab Med. 42:178–87. DOI: 10.3343/alm.2022.42.2.178. PMID: 34635611. PMCID: PMC8548247.

7. Vanmassenhove J, Van Biesen W, Vanholder R, Lameire N. 2019; Subclinical AKI: ready for primetime in clinical practice? J Nephrol. 32:9–16. DOI: 10.1007/s40620-018-00566-y. PMID: 30523562.

8. Zou C, Wang C, Lu L. 2022; Advances in the study of subclinical AKI biomarkers. Front Physiol. 13:960059. DOI: 10.3389/fphys.2022.960059. PMID: 36091391. PMCID: PMC9449362.

9. Ostermann M, Zarbock A, Goldstein S, Kashani K, Macedo E, Murugan R, et al. 2020; Recommendations on acute kidney injury biomarkers from the acute disease quality initiative consensus conference: a consensus statement. JAMA Netw Open. 3:e2019209. DOI: 10.1001/jamanetworkopen.2020.19209. PMID: 33021646.

10. Di Somma S, Magrini L, De Berardinis B, Marino R, Ferri E, Moscatelli P, et al. 2013; Additive value of blood neutrophil gelatinase-associated lipocalin to clinical judgement in acute kidney injury diagnosis and mortality prediction in patients hospitalized from the emergency department. Crit Care. 17:R29. DOI: 10.1186/cc12510. PMID: 23402494. PMCID: PMC4056001.

11. Cruz DN, de Cal M, Garzotto F, Perazella MA, Lentini P, Corradi V, et al. 2010; Plasma neutrophil gelatinase-associated lipocalin is an early biomarker for acute kidney injury in an adult ICU population. Intensive Care Med. 36:444–51. DOI: 10.1007/s00134-009-1711-1. PMID: 19956925. PMCID: PMC2820221.

12. Bihorac A, Chawla LS, Shaw AD, Al-Khafaji A, Davison DL, Demuth GE, et al. 2014; Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication. Am J Respir Crit Care Med. 189:932–9. DOI: 10.1164/rccm.201401-0077OC. PMID: 24559465.

13. Albert A, Radtke S, Blume L, Bellomo R, Haase M, Stieger P, et al. 2023; Neutrophil gelatinase-associated lipocalin cutoff value selection and acute kidney injury classification system determine phenotype allocation and associated outcomes. Ann Lab Med. 43:539–53. DOI: 10.3343/alm.2023.43.6.539. PMID: 37387487.